Market revenue in 2023 | USD 201.4 million |
Market revenue in 2030 | USD 311.5 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 84.31% in 2023. Horizon Databook has segmented the Spain hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Breast cancer is the most frequent malignancy in Spanish women, with an incidence of around 85 cases per 100,000 women, as per International Agency for Research on Cancer data. The Spanish Medical Oncology Society (SEOM) laid down clinical criteria for selection of inherited breast cancer patients through a clinical guideline that would be eligible for genetic testing.
European Society for Medical Oncology provides its own guidelines that focus on prevention and screening of cancer among individuals known to harbor pathogenic BRCA1/BRCA2 mutations. The presence of these mutations’ accounts for majority of hereditary breast and ovarian cancer syndromes.
Spanish regulatory framework for hereditary testing of inherited cancer cases is expected to streamline cancer testing in Spain, which, in turn, increases the adoption of accurate and improved testing solutions across the Spanish market.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Spain hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account